TreatmentTrends®: Rheumatoid Arthritis 2014 (US) explores the use of conventional DMARDs as well as biologics or Xeljanz for the treatment of rheumatoid arthritis (RA). One hundred U.S. rheumatologists were surveyed to investigate current and anticipated use of biologics or Xeljanz, perceived strengths and weaknesses of key marketed RA products, sales force performances, and products in development.
Questions Answered in This Report:
- Newer alternative mechanism of action (MOA) agents are capturing more brand share at the expense of the established TNF-? inhibitors. How has market share evolved with the introduction of more recently launched RA products?
- How a product for RA performs on certain efficacy attributes is an important factor in rheumatologists’ prescribing decisions. How can newcomers become competitive in the well-established RA disease market?
- Most rheumatologists are aware of forthcoming biosimilars for RA and accordingly expect biologic prescription to increase. How will the availability of biosimilars for RA impact rheumatologists’ prescribing?
Markets covered: United States.
Primary research: 100 U.S. rheumatologists who are currently in clinical practice and are treating a minimum of 100 RA patients, at least 50 of whom were required to be on biologic agents or Xeljanz.
Methodology: 30-minute online survey with several open-ended questions for qualitative feedback.
Emerging therapies: Phase III: 4 drugs.